Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for berotralstat

  1. Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)

    Evidence-based recommendations on berotralstat (Orladeyo) for preventing recurrent attacks of hereditary angioedema in people 12 years and older.

    Technology appraisal guidance
    Published
    20 October 2021
    View recommendations

    Sections for TA738

  2. Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]

    In development [GID-TA11452] Expected publication date: 21 August 2025

    Technology appraisal guidance
    In development

  3. Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]

      Status ...

    Technology appraisal guidance
    Topic selection

  4. NICE real-world evidence framework (ECD9)

    The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence